Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2025-12-30 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
第四届董事会第二十次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 20th meeting of the 4th Board of Directors of the company. It includes details about the meeting's convening, attendance, and voting results on specific agenda items such as the appointment of an accounting firm and the calling of a shareholders' meeting. The document does not contain financial statements or detailed financial data but focuses on board decisions and governance matters. It also references other announcements for further details. Therefore, this document fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2025-12-30 Chinese
第四届董事会审计委员会2025年第六次会议的审查意见
Audit Report / Information Classification · 95% confidence The document is a formal opinion from the Audit Committee of the Board regarding the appointment of an accounting firm for the audit of the company's 2025 financial report and internal control. It references relevant laws and regulations and is signed by committee members. The content is focused on audit-related matters and does not contain the audit report itself, but rather the committee's review and recommendation. This fits the definition of an Audit Report / Information filing, which includes audit reports and related opinions from audit committees. The document length is short but contains substantive audit committee opinion, not just an announcement or certification. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2025
2025-12-30 Chinese
第四届董事会独立董事2025年第四次专门会议的审查意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from the independent directors of the board regarding a specific financing matter (application for a comprehensive credit line and guarantee by a subsidiary). It references relevant laws and regulations and concludes with the independent directors' approval to submit the proposal to the board. The content is focused on board/management oversight and approval rather than financial results, audit, or shareholder voting. The document length is short (749 characters) and does not contain financial statements or detailed financial data. It is not an announcement of a report but a formal board-related opinion. Therefore, it fits best under Board/Management Information (MANG).
2025-12-23 Chinese
关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2026 first extraordinary general meeting (临时股东会) of shareholders for 赛隆药业集团股份有限公司. It details the meeting date, voting procedures, agenda items, and proxy voting instructions. It does not contain financial statements or results but is an announcement of a shareholder meeting and related voting information. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than the solicitation materials or proxy statement itself, it is best classified as a Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters and is a detailed notice for shareholders to vote on specific proposals, consistent with PSI filings.
2025-12-23 Chinese
关于公司向银行申请综合授信额度并接受全资子公司担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding its application for a comprehensive credit facility from a bank, including details about the credit amount, guarantee by a subsidiary, board resolutions, and authorization for related business activities. It does not contain financial statements or detailed financial performance data. The document is relatively short (1169 characters) and focuses on financing activities and corporate decisions related to credit facilities. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2025-12-23 Chinese
第四届董事会第十九次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at the 19th meeting of the 4th Board of Directors of Sailong Pharmaceutical Group Co., Ltd. It details the meeting's attendance, the agenda items discussed, and the voting results. The content focuses on board decisions such as organizational restructuring, capital increase via debt-to-equity swap, bank credit application, and convening a shareholders' meeting. It references other announcements for detailed information but itself is a summary of board meeting resolutions. There is no financial data, audit information, or report publication mentioned. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2025-12-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.